Future investigations could explore joint analyses involving SP-D with other potential biomarkers such as KL-6, CA-125, and CA19-9, members of the matrix metalloproteinase family, and chemokine family members, to further enhance the ability of SP-D in assessing disease status among patients with ILD. Here, MUC1 is linked to interstitial lung disease.